Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthSource vs Voxy

HealthSource
Graded #97

Higher grade

vs+9.100000000000001
Voxy
Graded #280

Lower grade

The verdict

HealthSource takes it — 71.2/100 to 62.1/100.

HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthSource +16
66
50
Dose & formulationHealthSource +19
83
64
Clinical oversightVoxy +2
80
82
Labs & monitoringVoxy +9
54
63
FulfillmentHealthSource +2
80
78
Contract termsHealthSource +35
55
20
HealthSource · left barVoxy · right bar

The numbers

MetricHealthSourceVoxy
WeighScore71.2/10062.1/100
GradeCC
Scorecard rank#97#280
Semaglutide$199/mo (all doses, compounded)$179/mo (compounded)
Tirzepatide$299/mo (all doses, compounded)$299/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
HealthSource

Graded #97 · C

Strengths

  • Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
  • 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
  • Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
  • Subscription auto-refund if monthly reassessment is not completed
  • Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping

Where it loses points

  • No physician names or clinical leadership disclosed on public pages
  • No LegitScript certification found
  • 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
  • Labs not mentioned on any product page — baseline bloodwork protocol unknown
  • WooCommerce e-commerce storefront may feel more transactional than clinical
Voxy

Graded #280 · C

Strengths

  • Names both its compounding pharmacy (VialsRX, Houston TX) and its prescribing medical group (Arora Health & Aesthetics) — most name neither
  • Publishes the full price ladder for both drugs across 1-, 3-, 6- and 12-month terms before you start the assessment
  • One price covers the provider visit, medication, injection supplies, shipping and monthly check-ins — no separate membership fee
  • True month-to-month option at $179 semaglutide / $299 tirzepatide with no commitment required
  • Free assessment with no charge to see if you qualify, and no labs required to start

Where it loses points

  • No terms of service anywhere on the site — /terms, /terms-of-service and /terms-of-use all return 404
  • No refund policy published; the only stated commitment language is 'cancel anytime'
  • Advertised 'Starting at $129/mo' is the 12-month prepay rate — month-to-month is $179 semaglutide and $299 tirzepatide
  • No public list of states served; availability depends on where affiliated providers are licensed
  • The prescribing nurse practitioner is not named — 'provider details available during your consultation'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard